Abstract
Objectives:
To evaluate the effects of using Exparel® bupivacaine liposome suspension 1.3% (13.3 mg/mL) as an adjunct to standard of care medication in adult tonsillectomy patients.
Study Design:
Randomized controlled trial.
Setting:
Community Hospital.
Methods:
The study arm (n = 22) received Exparel® bupivacaine liposome suspension 1.3% (13.3 mg/mL) as an adjunct to the standard of care (SOC) medication bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 μg/mL). The control group (n = 20) received SOC bupivacaine HCl 0.25% with epinephrine (5 μg/mL). All injections were administered after the excision of the tonsil, prior to conclusion of the operative procedure. Pre- and post-operative clinicopathologic variables of interest were collated from electronic medical records and daily pain diaries. Results were analyzed via standard univariate statistics, linear mixed models, and Poisson regression.
Results:
The Exparel® + SOC group experienced significantly less pain at post operative day (POD) 3 compared to the control group (P < .05). Mean pain score decreased on average by 1.23 points in the Exparel® + SOC group and increased on average by 0.39 points in the control group (adj. P-value < .001). Similarly, analysis showed that maximum pain score decreased on average by 0.64 points in the Exparel® + SOC and increased on average by 0.61 points the control group (adj. P-value < .001). There was a statistically significant decrease in dose of oxycodone use between POD 3 and POD 5 within the Exparel® + SOC group (16.39 vs 7.22 mg, P-value = .035). The relative proportion of patients who took oxycodone was less in the Exparel® + SOC group compared to the control group across all PODs.
Conclusion:
Use of Exparel® in adult tonsillectomy may decrease post-operative opioid use compared to standard of care treatment. These findings may serve as guidance for best practices in adult tonsillectomy.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
